Biotech Patent Litigation Evolves Amid Rising Biosimilar Competition and Cross-Border Disputes
2025 marks a pivotal year for biotech patent enforcement with landmark cases on aflibercept formulations spanning Europe, the US, and Asia, highlighting shifting litigation dynami…
The year 2025 witnessed significant developments in biotech patent litigation, particularly involving biosimilars of aflibercept, a key biologic marketed as Eylea®. Litigation activity intensified across multiple jurisdictions, including England, Germany, the United States, South Korea, and Japan, reflecting a more co…